PE20211794A1 - Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico - Google Patents

Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico

Info

Publication number
PE20211794A1
PE20211794A1 PE2020001685A PE2020001685A PE20211794A1 PE 20211794 A1 PE20211794 A1 PE 20211794A1 PE 2020001685 A PE2020001685 A PE 2020001685A PE 2020001685 A PE2020001685 A PE 2020001685A PE 20211794 A1 PE20211794 A1 PE 20211794A1
Authority
PE
Peru
Prior art keywords
glp
agonist
amino
salt
caprylic acid
Prior art date
Application number
PE2020001685A
Other languages
English (en)
Inventor
Simon Bjerregaard
Rahbek Ulrik Lytt
Sassene Philip Jonas
Water Jorrit Jeroen
Andreas Vegge
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PE20211794A1 publication Critical patent/PE20211794A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La invencion se refiere a composiciones farmaceuticas que comprenden i) un agonista de GLP-1 seleccionado del grupo que consiste en liraglutida, semaglutida, agonista B de GLP-1 y agonista C de GLP-1; ii) una sal del acido N-(8-(2-hidroxibenzoil)amino)caprilico (NAC); y iii) un hidrotropo seleccionado de nicotinamida o resorcinol, el cual es capaz de aumentar la solubilidad de SNAC al menos 5 veces o tal como al menos 10 veces. Tambien refieren procesos para la preparacion de dichas composiciones; las cuales muestran una absorcion acelerada, que permite la captacion rapida y eficiente del ingrediente farmaceutico activo; siendo utiles para tratar la diabetes y/o la obesidad.
PE2020001685A 2018-05-07 2019-05-06 Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico PE20211794A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18171046 2018-05-07
PCT/EP2019/061502 WO2019215063A1 (en) 2018-05-07 2019-05-06 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
PE20211794A1 true PE20211794A1 (es) 2021-09-09

Family

ID=62134107

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001685A PE20211794A1 (es) 2018-05-07 2019-05-06 Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico

Country Status (19)

Country Link
US (2) US11622996B2 (es)
EP (1) EP3790575A1 (es)
JP (2) JP7164628B2 (es)
KR (1) KR20210008353A (es)
CN (1) CN112153979A (es)
AR (1) AR115283A1 (es)
AU (1) AU2019264783A1 (es)
BR (1) BR112020021717A2 (es)
CA (1) CA3097944A1 (es)
CL (1) CL2020002797A1 (es)
CO (1) CO2020014570A2 (es)
IL (1) IL277857A (es)
MA (1) MA52556A (es)
MX (1) MX2020011308A (es)
PE (1) PE20211794A1 (es)
PH (1) PH12020551691A1 (es)
SG (1) SG11202009978WA (es)
TW (1) TWI829687B (es)
WO (1) WO2019215063A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN115461044A (zh) 2020-04-29 2022-12-09 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
TW202227474A (zh) 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ－１及澱粉素受體之共促效劑
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
EP4360645A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition containing glp-1 compound
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
TW202346324A (zh) 2022-05-10 2023-12-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024008904A2 (en) * 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69019534T2 (de) 1989-12-21 1995-09-21 Novo Nordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2002098348A2 (en) 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
CN1787830A (zh) * 2003-05-14 2006-06-14 爱密斯菲尔科技公司 用于传送肽yy和pyy激动剂的组合物
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2563379A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
CN1968919A (zh) * 2004-04-16 2007-05-23 爱密斯菲尔科技公司 用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
AU2005240206B2 (en) * 2004-05-06 2011-04-07 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20090111730A1 (en) 2004-07-08 2009-04-30 Novo Nordisk A/S Polypeptide protracting tags
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
EA200701362A1 (ru) 2004-12-22 2008-08-29 Сентокор, Инк. Агонисты glp-1, композиции, способы и применения
AU2005319432A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
US20080153779A1 (en) * 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
WO2007076319A2 (en) 2005-12-22 2007-07-05 Centocor, Inc. Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
EP2049567A2 (en) 2006-07-18 2009-04-22 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
US20090209469A1 (en) 2006-08-04 2009-08-20 Dennis Kim Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US10875826B2 (en) 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
US20100080829A1 (en) 2007-04-11 2010-04-01 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
EP1980245A1 (en) 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
GB0707662D0 (en) * 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009075859A2 (en) 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2009274983A (ja) * 2008-05-14 2009-11-26 Kowa Co ニコチン酸アミドを含有する経口医薬組成物
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
AU2009283821B2 (en) 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
US8425968B2 (en) 2009-06-19 2013-04-23 Pepsico., Inc. Beverage preservative system containing pimaricin-cyclodextrin complex
US20120065255A1 (en) 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
CA2790708A1 (en) 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US10933120B2 (en) * 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HRP20231613T1 (hr) * 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2863895B1 (en) * 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
BR112015026325A2 (pt) * 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
CN103405753B (zh) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
JP2018505173A (ja) 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス 錠剤コアと即時放出コーティングとを含む経口ｇｌｐ−１投与用の医薬組成物
BR112017026853A2 (pt) 2015-06-16 2018-08-14 Sun Pharma Advanced Research Company Limited composição de ação prolongada
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
JP7053480B2 (ja) 2016-03-03 2022-04-12 ノヴォ ノルディスク アー／エス Ｇｌｐ－１誘導体及びその使用
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN109996547A (zh) 2016-10-31 2019-07-09 苏达有限公司 粘膜活性剂递送
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
SG11202009467YA (en) 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues

Also Published As

Publication number Publication date
KR20210008353A (ko) 2021-01-21
CA3097944A1 (en) 2019-11-14
AR115283A1 (es) 2020-12-16
CO2020014570A2 (es) 2021-03-08
TW202015722A (zh) 2020-05-01
CN112153979A (zh) 2020-12-29
WO2019215063A8 (en) 2020-07-02
MX2020011308A (es) 2020-11-18
US20230087952A1 (en) 2023-03-23
CL2020002797A1 (es) 2021-02-19
PH12020551691A1 (en) 2021-07-19
US20210236601A1 (en) 2021-08-05
WO2019215063A1 (en) 2019-11-14
SG11202009978WA (en) 2020-11-27
AU2019264783A1 (en) 2020-12-10
JP2022191439A (ja) 2022-12-27
JP7164628B2 (ja) 2022-11-01
JP2021523149A (ja) 2021-09-02
MA52556A (fr) 2021-03-17
EP3790575A1 (en) 2021-03-17
BR112020021717A2 (pt) 2021-01-26
IL277857A (en) 2020-11-30
US11622996B2 (en) 2023-04-11
TWI829687B (zh) 2024-01-21

Similar Documents

Publication Publication Date Title
PE20211794A1 (es) Composiciones solidas que comprenden un agonista de glp-1 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CL2021002713A1 (es) Procedimiento para la preparación de derivados de oxadiazol microbiocidas.
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
CL2020001899A1 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante.
UY37997A (es) Agentes antivirales contra la hepatitis b
UY38059A (es) Heterociclos sustituidos como agentes antivirales
CO6660514A2 (es) Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201792421A1 (ru) Амидозамещенные производные циклогексана
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2017008584A2 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
PE20221458A1 (es) Composiciones solidas que comprenden un inhibidor de pcsk9 y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
CO2017010065A2 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina
BR112022000490A2 (pt) Composição farmacêutica
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico